Genetic modification of source pigs for xenograft organs (heart, kidney, liver, lung) provide the only viable near-term solution to the critical worid-wide shortage of donor organs for human clinical transplantation. Functional inactivation of the pig alpha 1,3 gal gene (GTKO pigs), in combination with transgenic expression of a human complement inhibitor gene (hCD46) addresses both hyperacute gal-mediated antibody rejection, as well as, inhibition of non-gal antibody responses and complement pathway associated responses in vivo in pig-to-non-human primate (NHP) transplant studies. Further genetic modification of the source pigs has the potential to address both safety and efficacy issues, since by building immunosuppressant gene expression into the donor organ, one can modulate cell mediated rejection with reduced drug levels of exogenous agents, and by further adding human anti-thrombotic genes and anti-inflammatory genes, one can inhibit both humoral and cell-mediated rejection, as well as inflammatory responses and thrombosis , thus abrogating both early and chronic immune-mediated destruction, as well as acute vascular rejection of organ xenografts. The goal of this transgenic pig core is to produce genetically modified pigs as source animals, specifically for replacement organ procurement to meet the needs for in vitro, ex vivo, and in vivo studies (described in Projects 1-2) aimed at improving xeno-organ survival towards providing a humancompatible tissues, in sufficient scale, to overcome the deficiencies in donor organ availability for human patients. Pigs have been produced which express a dominant negative mutant of pig SLA class II genes (CIITA DN) resulting in functional suppression of T cell mediated activation. CIITA-transgenic pigs will be crossed onto the GTKO/hCD46 genetic background for use in NHP studies. Further, pigs with transgenic expression and function of the anti-thrombotic/anti-inflammatory genes, human thrombomodulin (hTM) and human endothelial cell protein C receptor (EPCR) will be combined with the GTKO/CD46/CIITA background in order to address AVR and thrombotic microangiopathy. Bioactivity of these therapeutic transgenes has been confirmed, and such pigs will be replicated by the pig core to meet the goals outlined in Projects 1-2.

Public Health Relevance

Transgenic pigs provide an unlimited and renewable resource aimed at overcoming the critical shortage donor organs for human clinical transplantation. Genetic modification of the source pigs has relevance not only in scale, but also safety and efficacy, since by removing specific pig genes, and adding human genes, one can not only prevent rejection, and reduce levels of immunosuppression, but also inhibit thrombosis and inflammation thus addressing current barriers to successful oia to human oraan transplantation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI090959-01
Application #
8009662
Study Section
Special Emphasis Panel (ZAI1-JBS-I (M1))
Project Start
2010-08-01
Project End
2015-07-31
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
1
Fiscal Year
2010
Total Cost
$243,948
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Zhang, Guoqiang; Hara, Hidetaka; Yamamoto, Takayuki et al. (2018) Serum amyloid a as an indicator of impending xenograft failure: Experimental studies. Int J Surg 60:283-290
Jagdale, Abhijit; Cooper, David K C; Iwase, Hayato et al. (2018) Chronic dialysis in patients with end-stage renal disease: Relevance to kidney xenotransplantation. Xenotransplantation :e12471
Iwase, Hayato; Yamamoto, Takayuki; Cooper, David K C (2018) Episodes of hypovolemia/dehydration in baboons with pig kidney transplants: A new syndrome of clinical importance? Xenotransplantation :e12472
Singh, Avneesh K; Chan, Joshua L; DiChiacchio, Laura et al. (2018) Cardiac xenografts show reduced survival in the absence of transgenic human thrombomodulin expression in donor pigs. Xenotransplantation :e12465
Yamamoto, Takayuki; Li, Qi; Hara, Hidetaka et al. (2018) Data on B cell phenotypes in baboons with pig artery patch grafts receiving conventional immunosuppressive therapy. Data Brief 20:1965-1974
Cooper, David K C; Ezzelarab, Mohamed; Iwase, Hayato et al. (2018) Perspectives on the Optimal Genetically Engineered Pig in 2018 for Initial Clinical Trials of Kidney or Heart Xenotransplantation. Transplantation 102:1974-1982
Iwase, Hayato; Klein, Edwin C; Cooper, David Kc (2018) Physiologic Aspects of Pig Kidney Transplantation in Nonhuman Primates. Comp Med 68:332-340
Cimeno, Arielle; French, Beth M; Powell, Jessica M et al. (2018) Synthetic liver function is detectable in transgenic porcine livers perfused with human blood. Xenotransplantation 25:
Yamamoto, Takayuki; Li, Qi; Hara, Hidetaka et al. (2018) B cell phenotypes in baboons with pig artery patch grafts receiving conventional immunosuppressive therapy. Transpl Immunol 51:12-20
Jagdale, Abhijit; Iwase, Hayato; Klein, Edwin et al. (2018) Will donor-derived neoplasia be problematic after clinical pig organ or cell xenotransplantation? Xenotransplantation :e12469

Showing the most recent 10 out of 115 publications